Cerenome Reports Q2 2026 Net Loss of $9.0M, Cash at $8.6M
CNSY sits 21% above its 52-week low of $2.9.
Summary
Cerenome reported a Q2 2026 net loss of $9.0 million on $0.4 million in grant revenue, with cash and investments of $8.6 million. The company affirmed its 2026 milestones but faces a significant cash burn as it scales CNSide and advances REYOBIQ.
Key Events · Earnings and Guidance · CNSY
-
Q2 Net Loss Widens to $9.0M
Net loss of $9.0 million ($1.31/share) in Q2 2026 versus net income of $5.2 million ($0.62/share) in Q2 2025, which included a $6.5 million non-cash derivative fair-value gain.
-
Cash Position at $8.6M
Cash, cash equivalents and investments totaled $8.6 million as of June 30, 2026, down from $8.6 million at December 31, 2025, with operating cash burn of $13.4 million in H1 2026.
-
CNSide Commercial Progress
Performed 232 CNSide CSF tests in H1 2026 and achieved 150 million covered lives for commercial payer coverage, meeting the 2026 corporate objective by mid-year.
-
REYOBIQ Clinical Milestones
ReSPECT-LM trial approximately one-third enrolled with no dose-limiting toxicities; ReSPECT-GBM full enrollment expected in 2026 with data readout in Q1 2027; ReSPECT-PBC first dosing expected in Q3 2026.
Analysis · CNSY · Industrial Applications And Services
Cerenome's second quarter results show a sharp widening of losses as the company invests heavily in its CNSide commercial rollout and REYOBIQ clinical trials. The net loss of $9.0 million compares to net income of $5.2 million a year ago, which had benefited from a one-time $6.5 million derivative fair-value gain. Cash and investments of $8.6 million provide limited runway given the current burn rate, making future capital raises likely. The company affirmed its 2026 milestones, including full enrollment in the ReSPECT-GBM trial and expansion of CNSide payer coverage, but the financials underscore the cash consumption required to reach those goals.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNSY was trading at $3.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $2.90 to $23.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.